Leaflet Unither

Unither Pharmaceuticals CEO Eric Goupil said, “We are extremely pleased to benefit from the support of Empire State Development, Monroe County, RG & E, and Greater Rochester Enterprise in extending our facility while reducing our carbon footprint. Unither’s purpose is to provide innovative, competitive, and easy to use solutions to simplify the life of patients around the world while reducing our Carbon footprint and our impact on the environment and taking care of our employees to offer them job opportunities and careers possibilities. This expansion will enable our Rochester plant to increase its capacity on preservative-free sterile products and will allow us to support our customers in their growth. Thanks to the dynamism of all local stakeholders, we are confident to reach a leadership position in the US.”

Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the successful manufacturing of the three registration batches of PXT3003 oral solution sachets in the United States (U.S.), utilizing an innovative and state-of-the-art “form-fill-seal liquid sachets technology” and initiated the new drug application (NDA) registration stability at Unither Manufacturing LLC in Rochester, NY (USA).

This scientific review delves into collaborative research conducted by teams from Unither Développement Bordeaux alongside partners from various institutions including Université Paris Cité, CNRS, INSERM, UTCBS, Unité de Technologies Chimiques et Biologiques pour la Santé, Département de Recherche et Développement (DRDP), Agence Générale des Equipements et Produits de Santé (AGEPS), Assistance Publique Hôpitaux de Paris (AP-HP), as well as the Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO) and the School of Pharmaceutical Sciences at the University of Geneva.

BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
 
The seed round was co-led by UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital, with participation from one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.Proceeds to fund first-in-human trial of breakthrough topical Ophthalmic Inserts in the treatment of Glaucoma and to advance a second program in Macular Edema, thus targeting the two leading causes of blindness.BIOPHTA’s unique technology is poised to disrupt the treatment of both the front- and back-of-the-eye. The company is developing the first continuous topical retina treatment to free patients from the need for intraocular injections.